TABLE 68

Sensitivity analysis of AG-revised base-case scenario, with alternative assumed values of the incidence rate of grade 3 and 4 FN during second-line docetaxel 3-weekly monotherapy

ScenarioFN incidence (%)ErlotinibDocetaxelIncrementalICER
Total costTotal QALYsTotal costTotal QALYsCostQALYs£/QALY
AG-revised base case6.35£14,0490.4863£13,5040.5930£545–0.1067–£5112 (dominated)
Decision Support Unit estimate5.95£14,0490.4863£13,4820.5931£567–0.1067–£5312 (dominated)
TAILOR trial41 (all patients)3.85£14,0490.4863£13,3650.5939£684–0.1076–£6353 (dominated)
Weighted average (all trials)7.26£14,0490.4863£13,5540.5926£495–0.1063–£4654 (dominated)
Weighted average (2 high-incidence trials)10.80£14,0490.4863£13,7490.5913£300–0.1050–£2854 (dominated)
Weighted average (15 low-incidence trials)5.03£14,0490.4863£13,4310.5934£618–0.1072–£5768 (dominated)
Maximum trial12.68£14,0490.4863£13,8530.5906£196–0.1044–£1876 (dominated)

From: Appendix 8, Rates of febrile neutropenia associated with treatment with docetaxel

Cover of Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Health Technology Assessment, No. 19.47.
Greenhalgh J, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2015 Jun.
Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Greenhalgh et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.